| 國立成功大學 |
2006-09 |
Response to comments on: Fermentative hydrogen production with Clostridium butyricum CGS5 isolated from anaerobic sewage sludge (Int J Hydrogen Energy, 2005;30 : 1063-70)
|
Chang, Jo-Shu; Lee, Kuo-Shing |
| 臺大學術典藏 |
2021-09-13T05:41:52Z |
Response to Dell'Osso and Elli
|
Eaton W.W.; LIAN-YU CHEN; Dohan F.C.; Jr, Kelly D.L.; Cascella N. |
| 國立政治大學 |
2018-11 |
Response to Demand Uncertainty of Supply Chains: A Value-Focused Approach with AHP and TOPSIS
|
羅明琇; Lo, Sonia Ming-Shiow; Chen, J.; Liu, T.S. |
| 臺大學術典藏 |
2018-09-10T09:26:20Z |
Response to Discussant of "Does the Control Based Approach to Consolidated Statements Better Reflect Market Value than the Ownership-based Approach?"
|
RONG-RUEY DUH;WEN-HSIN HSU; RONG-RUEY DUH; WEN-HSIN HSU; RONG-RUEY DUH; WEN-HSIN HSU |
| 國立臺灣大學 |
2010 |
Response to Dr. Nuri Karadurmus
|
林彥宏; 何奕倫; 陳明豐; LIN, YEN-HUNG; HO, YI-LWUN; CHEN, MING-FONG |
| 臺大學術典藏 |
2020-12-01T07:10:18Z |
Response to Dr. Nuri Karadurmus
|
Lin Y.-H.;Yi-Lwun Ho;Chen M.-F.; Lin Y.-H.; YI-LWUN HO; Chen M.-F. |
| 臺大學術典藏 |
2010 |
Response to Dr. Nuri Karadurmus
|
YEN-HUNG LIN; Ho Y.-L.; Chen M.-F. |
| 國家衛生研究院 |
2003-03 |
Response to efavirenz plus two nucleoside reverse-transcriptase inhibitors in patients with advanced stage human immunodeficiency virus-1 infection in Taiwan
|
Deng, S;Chen, M;Hsieh, S;Sheng, W;Hsiao, C;Hung, C;Chang, S |
| 國立臺灣大學 |
2003 |
Response to Efavirenz Plus Two Nucleoside Reverse-Transcriptase Inhibitors in Patients with Advanced Stage Human Immunodeficiency Virus-1 Infection in Taiwan
|
陳茂源; 謝思民; 盛望徽; 蕭金福; 洪健清; 張上淳; CHEN, MAO-YUAN; HSIEH, SZU-MIN; SHENG, WANG-HUEI; HSIAO, CHIN-FU; HUNG, CHIEN-CHING; CHANG, SHAN-CHWEN |
| 臺大學術典藏 |
2018-09-10T04:24:21Z |
Response to efavirenz plus two nucleoside reverse-transcriptase inhibitors in patients with advanced stage human immunodeficiency virus-1 infection in Taiwan
|
Deng, S.-C. and Chen, M.-Y. and Hsieh, S.-M. and Sheng, W.-H. and Hsiao, C.-F. and Hung, C.-C. and Chang, S.-C.; SZU-MIN HSIEH |
| 臺大學術典藏 |
2018-09-10T04:26:53Z |
Response to efavirenz plus two nucleoside reverse-transcriptase inhibitors in patients with advanced stage human immunodeficiency virus-1 infection in Taiwan
|
Deng, S.-C. and Chen, M.-Y. and Hsieh, S.-M. and Sheng, W.-H. and Hsiao, C.-F. and Hung, C.-C. and Chang, S.-C.; CHIEN-CHING HUNG |
| 臺大學術典藏 |
2003 |
Response to efavirenz plus two nucleoside reverse-transcriptase inhibitors in patients with advanced stage human immunodeficiency virus-1 infection in Taiwan
|
Chang S.-C.; CHIEN-CHING HUNG; Hsiao C.-F.; Sheng W.-H.; Hsieh S.-M.; Chen M.-Y.; Deng S.-C.; Deng S.-C.;Chen M.-Y.;Hsieh S.-M.;Sheng W.-H.;Hsiao C.-F.;Chien-Ching Hung;Chang S.-C. |
| 臺大學術典藏 |
2020-12-30T02:44:28Z |
Response to efavirenz plus two nucleoside reverse-transcriptase inhibitors in patients with advanced stage human immunodeficiency virus-1 infection in Taiwan
|
Deng S.-C.;Chen M.-Y.;Hsieh S.-M.;Sheng W.-H.;Hsiao C.-F.;Hung C.-C.;Shan-Chwen Chang; Deng S.-C.; Chen M.-Y.; Hsieh S.-M.; Sheng W.-H.; Hsiao C.-F.; Hung C.-C.; SHAN-CHWEN CHANG |
| 臺大學術典藏 |
2021-02-26T02:00:25Z |
Response to efavirenz plus two nucleoside reverse-transcriptase inhibitors in patients with advanced stage human immunodeficiency virus-1 infection in Taiwan
|
Deng S.-C.;Chen M.-Y.;Hsieh S.-M.;Wang-Huei Sheng;Hsiao C.-F.;Hung C.-C.;Chang S.-C.; Deng S.-C.; Chen M.-Y.; Hsieh S.-M.; WANG-HUEI SHENG; Hsiao C.-F.; Hung C.-C.; Chang S.-C. |
| 臺大學術典藏 |
2021-12-01T02:30:28Z |
Response to efavirenz plus two nucleoside reverse-transcriptase inhibitors in patients with advanced stage human immunodeficiency virus-1 infection in Taiwan
|
Deng S.-C.; Chen M.-Y.; Hsieh S.-M.; Sheng W.-H.; Hsiao C.-F.; CHIEN-CHING HUNG; Chang S.-C. |
| 臺大學術典藏 |
2003 |
Response to efavirenz plus two nucleoside reverse-transcriptase inhibitors in patients with advanced stage human immunodeficiency virus-1 infection in Taiwan
|
Hung C.-C.; Hsiao C.-F.; Sheng W.-H.; SZU-MIN HSIEH; Chen M.-Y.; Deng S.-C.; Deng S.-C.;Chen M.-Y.;Szu-Min Hsieh;Sheng W.-H.;Hsiao C.-F.;Hung C.-C.;Chang S.-C.; Chang S.-C. |
| 義守大學 |
2006-01 |
Response to fluoxetine and serotonin 1A receptor (C-1019G) polymorphism in Taiwan Chinese major depressive disorder
|
C-J Hong;T-J Chen;Y W-Y Yu;S-J Tsai |
| 臺大學術典藏 |
2021-03-09T01:47:30Z |
Response to Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in?chronic hepatitis B patients
|
TUNG-HUNG SU; Kao J.-H. |
| 臺大學術典藏 |
2021-09-04T06:11:05Z |
Response to Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in?chronic hepatitis B patients
|
Su T.-H.; JIA-HORNG KAO |
| 國立臺灣大學 |
1998 |
Response to health physics: response to Chen
|
Chang WP; 王榮德Response to health physics: response to Chen; Chang WP; Wang Jung-DerResponse to health physics: response to Chen |
| 中山醫學大學 |
2009 |
Response to hypercapnic challenge is associated with successful weaning from prolonged mechanical ventilation due to brain stem lesions
|
Wu, Y.-K.;Lee, C.-H.;Shia, B.-C.;Tsai, Y.-H.;Tsao, Tsao T.C.Y. |
| 臺大學術典藏 |
2022-08-19T06:48:44Z |
Response to Immune Checkpoint Inhibitors in Recurrent or Metastatic Esophageal Squamous Cell Carcinoma May Be Affected by Tumor Sites
|
Guo J.-C.; Lin C.-Y.; Lin C.-C.; Huang T.-C.; Lien M.-Y.; Lu L.-C.; Kuo H.-Y.; CHIH-HUNG HSU |
| 臺大學術典藏 |
2022-02-07T03:29:04Z |
Response to Immune Checkpoint Inhibitors in Recurrent or Metastatic Esophageal Squamous Cell Carcinoma May Be Affected by Tumor Sites
|
Guo J.-C.; Lin C.-Y.; Lin C.-C.; Huang T.-C.; Lien M.-Y.; Lu L.-C.; Kuo H.-Y.; CHIH-HUNG HSU |
| 臺大學術典藏 |
2022-03-15T03:29:02Z |
Response to Immune Checkpoint Inhibitors in Recurrent or Metastatic Esophageal Squamous Cell Carcinoma May Be Affected by Tumor Sites
|
Guo J.-C.; Lin C.-Y.; Lin C.-C.; TA-CHEN HUANG; Lien M.-Y.; Lu L.-C.; Kuo H.-Y.; Hsu C.-H. |
| 臺大學術典藏 |
2022-09-15T01:08:47Z |
Response to Immune Checkpoint Inhibitors in Recurrent or Metastatic Esophageal Squamous Cell Carcinoma May Be Affected by Tumor Sites
|
Guo J.-C.; Lin C.-Y.; Chia-Chi Lin; Huang T.-C.; Lien M.-Y.; Lu L.-C.; Kuo H.-Y.; Hsu C.-H. |
